Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children
Pediatric Brain Stem Glioma
About this trial
This is an interventional treatment trial for Pediatric Brain Stem Glioma focused on measuring DIPG, Hypofractionated Radiotherapy, Radiotherapy, Median survival
Eligibility Criteria
Inclusion Criteria:
- Newly diagnosed patients with a diffuse intrinsic brainstem glioma, ages 3-18years, were eligible for this protocol.
- Patients were required to have symptoms for less than 3 months and at least two findings of the neurologic triad: cranial nerve deficits, ataxia, or long tract signs.
- No performance criteria were required for entry onto the study.
- The diagnosis of DIPG based on a high-quality, gadolinium- enhanced magnetic resonance imaging (MRI) scan containing at least T1, T2 MRIs with gadolinium contrast in three series, as well as diffusion imaging.
- Symptoms & signs of less than 3 months duration
Exclusion Criteria:
- Children were not eligible if they had received any prior therapy other than steroid
- The diagnosis of exophytic brainstem glioma
Sites / Locations
- Children's Cancer Hospital Egypt 57357
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Hypofractionated arm
Conventional arm
A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
The same planning and treatment procedures will be performed with the established conventional regimen: 54 Gy in 30 fractions giving 1.8 Gy per fraction.